Britain and America have secured a important bilateral deal that will maintain zero levies on UK drug shipments entering the US market.
The Terms of the Accord
As part of the deal, the UK has agreed to raise spending on pharmaceuticals through the public health system. This move secures that import taxes on these vital products will stay at zero for a timeframe of the next three years.
This agreement comes after previous warnings to dramatically increase tariffs on patented pharmaceutical products, with potential rates discussed up to one hundred percent.
"This deal between the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces much-needed fairness to American-British pharmaceutical trade," a statement declared.
Economic Importance
Medicines constitute one of the the United Kingdom's most significant goods shipped to the United States, which is easily the primary buyer for large British pharmaceutical firms.
Statistics reveal that in the year to the end of last September, the UK shipped medicines valued at £11.1bn to the US. This figure accounted for a significant portion of all goods exports in that timeframe.
"This guarantee secures work, boosts capital expenditure and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Specific British Pledges
The pact includes several specific commitments from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to double total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The amount manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. Previously, rebates topped 20%.
Industry Background
The deal takes place against a long-running dispute between the pharmaceutical industry and the UK government over drug pricing and approval rates.
The disagreement were heightened by claims that US patients were charged significantly more for the equivalent treatments than people in the other developed nations.
Recently, several large manufacturing plans in the UK have been halted or scrapped, while major investments have been directed toward American operations.
A senior figure acknowledged that the NHS must increase expenditure on drugs, noting that its spending on drugs had decreased as a proportion of its total funding over the past decade.
